Document Detail

Long-term outcome of treatment with ruxolitinib in myelofibrosis.
MedLine Citation:
PMID:  21995409     Owner:  NLM     Status:  In-Data-Review    
The initial encouraging activity of ruxolitinib in myelofibrosis appears to need some caveats when long-term efficacy is examined. The control of splenomegaly may not be durable, and the likelihood of leukemic progression or death is not dramatically lowered.
Ayalew Tefferi; Mark R Litzow; Animesh Pardanani
Related Documents :
17746619 - Mathematical groups.
19628879 - Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analy...
18953819 - Is laparoscopic resection appropriate for colorectal adenocarcinoma?
17576909 - Treatment of sudden sensorineural hearing loss: ii. a meta-analysis.
12933609 - Clustered encouragement designs with individual noncompliance: bayesian inference with ...
16205189 - Medical management of vulvar intraepithelial neoplasia.
24085549 - The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the tr...
25148409 - Vagarious successful treatment of recalcitrant warts in combination with co2 laser and ...
23283029 - Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicente...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  365     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1455-7     Citation Subset:  AIM; IM    
Mayo Clinic, Rochester, MN
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The avastin story.
Next Document:  Myotonia of the tongue.